-
4
-
5by Champiat, Stéphane Dercle, Laurent Ammari, Samy Massard, Christophe Hollebecque, Antoine Postel-Vinay, Sophie Chaput, Nathalie Eggermont, Alexander Marabelle, Aurélien Soria, Jean-Charles Ferté, Charles Published in Clinical cancer research (15.04.2017)“...While immune checkpoint inhibitors are disrupting the management of patients with cancer, anecdotal occurrences of rapid progression (i.e., hyperprogressive...”
-
6by Gainor, Justin F Shaw, Alice T Sequist, Lecia V Fu, Xiujun Azzoli, Christopher G Piotrowska, Zofia Huynh, Tiffany G Zhao, Ling Fulton, Linnea Schultz, Katherine R Howe, Emily Farago, Anna F Sullivan, Ryan J Stone, James R Digumarthy, Subba Moran, Teresa Hata, Aaron N Yagi, Yukako Yeap, Beow Y Engelman, Jeffrey A Mino-Kenudson, Mari Published in Clinical cancer research (15.09.2016)“...PD-1 inhibitors are established agents in the management of non-small cell lung cancer (NSCLC); however, only a subset of patients derives clinical benefit. To...”
-
7by Taube, Janis M Klein, Alison Brahmer, Julie R Xu, Haiying Pan, Xiaoyu Kim, Jung H Chen, Lieping Pardoll, Drew M Topalian, Suzanne L Anders, Robert A Published in Clinical cancer research (01.10.2014)“...Immunomodulatory drugs differ in mechanism-of-action from directly cytotoxic cancer therapies. Identifying factors predicting clinical response could guide...”
-
8by Kato, Shumei Goodman, Aaron Walavalkar, Vighnesh Barkauskas, Donald A Sharabi, Andrew Kurzrock, Razelle Published in Clinical cancer research (01.08.2017)“...Checkpoint inhibitors demonstrate salutary anticancer effects, including long-term remissions. PD-L1 expression/amplification, high mutational burden, and...”
-
9by Ren, Jiangtao Liu, Xiaojun Fang, Chongyun Jiang, Shuguang June, Carl H Zhao, Yangbing Published in Clinical cancer research (01.05.2017)“...Using gene-disrupted allogeneic T cells as universal effector cells provides an alternative and potentially improves current chimeric antigen receptor (CAR)...”
-
10by Jiao, Shiping Xia, Weiya Yamaguchi, Hirohito Wei, Yongkun Chen, Mei-Kuang Hsu, Jung-Mao Hsu, Jennifer L Yu, Wen-Hsuan Du, Yi Lee, Heng-Huan Li, Chia-Wei Chou, Chao-Kai Lim, Seung-Oe Chang, Shih-Shin Litton, Jennifer Arun, Banu Hortobagyi, Gabriel N Hung, Mien-Chie Published in Clinical cancer research (15.07.2017)“...To explore whether a cross-talk exists between PARP inhibition and PD-L1/PD-1 immune checkpoint axis, and determine whether blockade of PD-L1/PD-1 potentiates...”
-
11by Freeman-Keller, Morganna Kim, Youngchul Cronin, Heather Richards, Allison Gibney, Geoffrey Weber, Jeffrey S Published in Clinical cancer research (15.02.2016)“...Retrospective analysis of irAEs in melanoma patients treated with nivolumab. Data were pooled from 148 patients (33 resected, 115 unresectable) treated with...”
-
12by YU, Helena A ARCILA, Maria E REKHTMAN, Natasha SIMA, Camelia S ZAKOWSKI, Maureen F PAO, William KRIS, Mark G MILLER, Vincent A LADANYI, Marc RIELY, Gregory J Published in Clinical cancer research (2013)“...All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI). Smaller series have...”
-
13by Ballard, Peter Yates, James W T Yang, Zhenfan Kim, Dong-Wan Yang, James Chih-Hsin Cantarini, Mireille Pickup, Kathryn Jordan, Angela Hickey, Mike Grist, Matthew Box, Matthew Johnström, Peter Varnäs, Katarina Malmquist, Jonas Thress, Kenneth S Jänne, Pasi A Cross, Darren Published in Clinical cancer research (15.10.2016)“...Approximately one-third of patients with non-small cell lung cancer (NSCLC) harboring tumors with EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations...”
-
14by Dong, Zhong-Yi Zhong, Wen-Zhao Zhang, Xu-Chao Su, Jian Xie, Zhi Liu, Si-Yang Tu, Hai-Yan Chen, Hua-Jun Sun, Yue-Li Zhou, Qing Yang, Jin-Ji Yang, Xue-Ning Lin, Jia-Xin Yan, Hong-Hong Zhai, Hao-Ran Yan, Li-Xu Liao, Ri-Qiang Wu, Si-Pei Wu, Yi-Long Published in Clinical cancer research (15.06.2017)“...Although clinical studies have shown promise for targeting programmed cell death protein-1 (PD-1) and ligand (PD-L1) signaling in non-small cell lung cancer...”
-
15by Burstein, Matthew D Tsimelzon, Anna Poage, Graham M Covington, Kyle R Contreras, Alejandro Fuqua, Suzanne A W Savage, Michelle I Osborne, C Kent Hilsenbeck, Susan G Chang, Jenny C Mills, Gordon B Lau, Ching C Brown, Powel H Published in Clinical cancer research (01.04.2015)“...Genomic profiling studies suggest that triple-negative breast cancer (TNBC) is a heterogeneous disease. In this study, we sought to define TNBC subtypes and...”
-
16by Weide, Benjamin Martens, Alexander Hassel, Jessica C Berking, Carola Postow, Michael A Bisschop, Kees Simeone, Ester Mangana, Johanna Schilling, Bastian Di Giacomo, Anna Maria Brenner, Nicole Kaehler, Katharina Heinzerling, Lucie Gutzmer, Ralf Bender, Armin Gebhardt, Christoffer Romano, Emanuela Meier, Friedegund Martus, Peter Maio, Michele Blank, Christian Schadendorf, Dirk Dummer, Reinhard Ascierto, Paolo A Hospers, Geke Garbe, Claus Wolchok, Jedd D Published in Clinical cancer research (15.11.2016)“...Purpose: Biomarkers for outcome after immune-checkpoint blockade are strongly needed as these may influence individual treatment selection or sequence. We...”
-
17by Dudley, Jonathan C Lin, Ming-Tseh Le, Dung T Eshleman, James R Published in Clinical cancer research (15.02.2016)“...Initial results by Le and colleagues, which were published in the June 25, 2015 issue of the New England Journal of Medicine, report significant responses of...”
-
18by Weng, Wenhao Wei, Qing Toden, Shusuke Yoshida, Kazuhiro Nagasaka, Takeshi Fujiwara, Toshiyoshi Cai, Sanjun Qin, Huanlong Ma, Yanlei Goel, Ajay Published in Clinical cancer research (15.07.2017)“...Colorectal cancer is one of the most common malignancies worldwide. Recently, a novel circular RNA, ciRS-7, was proposed to be a potential miR-7 sponge. As...”
-
19by Marcus, Leigh Lemery, Steven J Keegan, Patricia Pazdur, Richard Published in Clinical cancer research (01.07.2019)“...The FDA approved pembrolizumab on May 23, 2017, for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite...”
-
20by Patnaik, Amita Kang, S Peter Rasco, Drew Papadopoulos, Kyriakos P Elassaiss-Schaap, Jeroen Beeram, Muralidhar Drengler, Ronald Chen, Cong Smith, Lon Espino, Guillermo Gergich, Kevin Delgado, Liliana Daud, Adil Lindia, Jill A Li, Xiaoyun Nicole Pierce, Robert H Yearley, Jennifer H Wu, Dianna Laterza, Omar Lehnert, Manfred Iannone, Robert Tolcher, Anthony W Published in Clinical cancer research (01.10.2015)“...This phase I study evaluated the safety, maximum tolerated dose, antitumor activity, and pharmacokinetics and pharmacodynamics of pembrolizumab in patients...”